Cite

    Yin, M., Hu, J., Yuan, Z., Luo, G., Yao, J., Wang, R., Liu, D., Cao, B., Wu, W., & Hu, Z. (2022). sTING agonist enhances the efficacy of programmed death-ligand 1 monoclonal antibody in breast cancer immunotherapy by activating the interferon-β signalling pathway. Cell cycle, 21(8), 767–779. http://access.bl.uk/ark:/81055/vdc_100153423063.0x000021